

tive amount of the conjugate of claim **27**, or a composition thereof comprising one or more carriers, excipients, diluents, and combinations thereof, to the patient.

39. The method of claim **38**, wherein the pathogenic population of cells is a cancer.

40. The method of claim **38**, wherein the pathogenic cells over-express folate receptors.

41. The method of claim **38**, wherein the conjugate binds to a folate receptor on the cancer cell and upon binding is internalized into the cancer cell.

* * * * *